NIKKEI 225
27,931.78+383.78(+1.39%)HANG SENG
26,680.63-641.35(-2.35%)CRUDE OIL
71.71-0.36(-0.50%)GOLD FUTURES
1,805.10+3.30(+0.18%)DOW
35,061.55+238.15(+0.68%)BTC-GBP
27,800.49+2,816.84(+11.27%)
AstraZeneca PLC (AZN.L)
| Previous close | 8,459.00 |
| Open | 8,452.00 |
| Bid | 7,900.00 x 0 |
| Ask | 8,720.00 x 0 |
| Day's range | 8,440.00 - 8,525.00 |
| 52-week range | 6,499.80 - 8,923.00 |
| Volume | 1,722,145 |
| Avg. volume | 3,400,294 |
| Market cap | 111.323B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 39.02 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.07 (2.38%) |
| Ex-dividend date | 25 Feb 2021 |
| 1y target est | N/A |
- Business Wire
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del., July 23, 2021--AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric patients (10 to 17 years) as an adjunct to diet and exercise.
- Globe Newswire
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in China of ORPATHYS® (savolitinib), HUTCHMED’s oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, which occurred on July 12, 2021. This follows less than three weeks after the June 22, 2021 approval of ORPATHYS® in China for the treatment of patients with locally
- Business Wire
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
WILMINGTON, Del., July 08, 2021--AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.
